Phase II Trial of 64Cu-ATSM PET/CT in Cervical Cancer (ACRIN6682)

• ClinicalTrials.gov Identifier: NCT00794339
• Recruitment Status: Terminated
• First Posted: November 20, 2008
• Results First Posted: January 28, 2021
• Last Update Posted: February 23, 2021
• Sponsor: American College of Radiology Imaging Network
• Collaborator: National Cancer Institute (NCI)
• Information provided by (Responsible Party): American College of Radiology Imaging Network

Study Description

Brief Summary:

RATIONALE: Diagnostic procedures, such as 64Cu-labeled diacetyl-bis[N4-methylthiosemicarbazone] (copper Cu 64-ATSM) PET/CT scans, may help doctors predict how patients will respond to treatment.

PURPOSE: This phase II trial is studying how well copper Cu 64-ATSM PET/CT scans work in predicting disease progression in patients undergoing standard of care treatment with cisplatin and radiation therapy (external beam and brachytherapy) per National Comprehensive Cancer Network (NCCN) guidelines for newly-diagnosed stage IB, stage II, stage III, or stage IVA cervical cancer via the Federation of Gynecology and Obstetrics (FIGO) staging systems.

Condition or disease	Intervention/treatment	Phase
Cervical Cancer	Drug: 64Cu-ATSM; Drug: FDG	Phase 2

Detailed Description:

OBJECTIVES:

Primary

• To define the role of pre-therapy ^64Cu-labeled diacetyl-bis(N4-methylthiosemicarbazone) (copper Cu 64-ATSM) in predicting prognosis and determining the behavior of an invasive squamous cell cervical cancer in patients with newly-diagnosed stage IB2-IVA cervical squamous cell carcinoma.
• To determine whether higher copper Cu 64-ATSM uptake is associated with lower progression-free survival of these patients after chemoradiotherapy.

Secondary

• To determine if higher copper Cu 64-ATSM uptake is associated with lower overall survival of these patients.
• To determine if higher copper Cu 64-ATSM uptake is associated with earlier primary cervical tumor recurrence and a higher rate of development of distant metastatic disease in these patients.
• To determine if higher copper Cu 64-ATSM uptake is associated with a lower frequency of complete metabolic response on 2-Deoxy-2-[18F]fluoroglucose (FDG) -PET/CT scan performed 3 months after completion of radiotherapy and chemotherapy.
• To estimate the accuracy of copper Cu 64-ATSM uptake as a predictor of progression-free survival, overall survival, primary tumor recurrence, and future development of distant metastatic disease in these patients.
• To evaluate the performance of copper Cu 64-ATSM uptake as a predictor of lymph node metastasis at study entry.
• To evaluate whether copper Cu 64-ATSM uptake correlates with tumor volume at study entry.
• To examine the relationship between tumor uptake of copper Cu 64-ATSM and other markers of tumor hypoxia, including Vascular endothelial growth factor (VEGF) , Glucose transporter 1 (GLUT1), Carbonic anhydrase IX (CA9/CA IX), and Osteopontin (OPN).
• To compare the predictive ability of pre-therapy copper Cu 64-ATSM-PET to that of post-therapy FDG-PET/CT scan.
• To assess whether pre-therapy FDG-PET/CT findings are predictive of progression-free survival.

OUTLINE: This is a multicenter study.

Patients receive copper Cu 64-ATSM IV and undergo PET/CT scan over 30 minutes 30-40 minutes later. Within 4 weeks after copper Cu 64-ATSM-PET/CT scan, patients begin planned concurrent standard of care chemoradiotherapy comprising 6 weeks of radiotherapy (external beam and brachytherapy)and weekly cisplatin administration per NCCN guidelines. Patients then undergo FDG-PET/CT scan 3 months after completion of chemoradiotherapy.

Tissue samples from previously collected cervical biopsy (obtained for diagnosis) are used for detecting hypoxic markers by immunohistochemistry analysis.

After completion of study intervention, patients are followed for every 3 months for 2 years and then every 6 months for 1 year.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 73 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Diagnostic
• Official Title: Copper Cu 64-ATSM and PET/CT Scan in Predicting Disease Progression in Patients With Newly-Diagnosed Stage IB, Stage II, Stage III, or Stage IVA Cervical Cancer Who Are Undergoing Chemoradiotherapy Per NCCN Guidelines
• Actual Study Start Date: July 29, 2009
• Actual Primary Completion Date: December 31, 2011
• Actual Study Completion Date: December 31, 2011

Arms and Interventions

Arm	Intervention/treatment
Experimental: Copper ATSM; pre-therapy pelvic 64Cu-ATSM-PET/CT with Pre- and post- therapy FDG PET/CT	Drug: 64Cu-ATSM; Other Names: copper 64; 64Cu Diacetyl-bis(N4-methylthiosemicarbazone); Drug: FDG; Other Names: fludeoxyglucose F 18; Fluorodeoxyglucose (18F); 18F-FDG; 18F-fluorodeoxyglucose

Outcome Measures

Primary Outcome Measures :

1. Relationship Between Copper Cu 64-ATSM Uptake in the Primary Tumor and Progression-free Survival 3 Years After Chemoradiotherapy [ Time Frame: every 3 months for first 2 years and every 6 months during year 3, up to 3 years ]

   Progression-free survival (PFS) evaluated every 3 months for first 2 years and every 6 months during year 3 to determine PFS at 3years.

   Cu64-ATSM Uptake measured within 14 days of baseline Uptake is a measure of activity within a tumor

   1. the maximum standardized uptake value (SUVmax = tracer uptake in ROI / (injected activity / patient weight))
   2. Tumor-to-Muscle uptake ratio (T/M, An FDG-PET/CT-guided circular region of interest of 1.0-1.5 cm in diameter is drawn around the most intense region of the primary tumor to calculate the maximum uptake within the region. In addition, regions of interest are drawn on bilateral gluteal muscle groups on at least 3 slices, and the mean uptake is calculated. The T/M is the ratio of these measurements.)

Secondary Outcome Measures :

1. Copper Cu 64-ATSM T/M Uptake and Overall Survival [ Time Frame: every 3 months for first 2 years and every 6 months during year 3, up to 3 years ]

   To determine if higher 64Cu-ATSM uptake on PET/CT is associated with lower Overall survival (OS) T/M Uptake measured within 14 days of baseline;

   Overall survival (OS) is measured every 3 months for first 2 years and every 6 months during year 3,until time of death or 3 years from baseline.

2. Relationship Between Copper Cu 64-ATSM Uptake and Complete Metabolic Response [ Time Frame: 3 months after completion of chemoradiation ]
   Complete metabolic response determined by FDG PET/CT performed 3 months after completion of chemoradiation By definition, metabolic response (as defined by NCI Concept ID: C3897320. https://www.ncbi.nlm.nih.gov/medgen/856914) is "the disappearance of metabolic tumor activity in target and non-target lesions, marked by a decrease in tumor standardized uptake value to the level of surrounding normal tissue (tumor uptake/normal uptake = ~1)"
3. Primary Tumor Recurrence [ Time Frame: every 3 months for first 2 years and every 6 months during year 3, up to 3 years ]
   To determine if higher 64Cu ATSM uptake is associated with earlier primary cervical tumor recurrence images were taken every 3 months for first 2 years and every 6 months during year 3, up to 3 years and evaluated for primary cervical tumor recurrence
4. Lymph Node Metastasis at Baseline [ Time Frame: Two weeks ]

   Lymph nodes were evaluated at 5 locations: Pelvic, Common Iliac, Para Aortic, Mediastinal, and Supraclavicular

   This outcome looks at the Association of Ratio of Tissue to Muscle (T/M) uptake with Lymph Node Metastases at Baseline

5. Relationship of Copper Cu 64-ATSM Uptake T/M Ratio and Carbonic Anhydrase IX (CA-IX) Percentage of Tumor Cells Staining Score as a Marker of Tumor Hypoxia [ Time Frame: baseline ]

   The Ratio of Tissue to Muscle (T/M) agent uptake measured at baseline was used as a predictor of Hypoxia Tumor Hypoxia was assessed with Carbonic anhydrase IX (CA-IX) markers using the

   Percentage of Tumor Cells Staining Score:

   0=<1% tumor cells; 1=1 33% tumor cells; 2=34 66% tumor cells; and 3=>66% tumor cells.

6. Relationship of Copper Cu 64-ATSM Uptake T/M Ratio and CA-IX Staining Intensity Score: as a Marker of Tumor Hypoxia [ Time Frame: baseline ]

   The Ratio of Tissue to Muscle (T/M) agent uptake measured at baseline was used as a predictor of Hypoxia Tumor Hypoxia was assessed with CA-IX markers using the

   Staining Intensity Score:

   0=No staining; 1=Weak staining; and 2=Moderate to strong staining.

7. Relationship of Copper Cu 64-ATSM Uptake T/M Ratio and CA-IX Composite Score as a Marker of Tumor Hypoxia [ Time Frame: Baseline ]

   The Ratio of Tissue to Muscle (T/M) agent uptake measured at baseline was used as a predictor of Hypoxia Tumor Hypoxia was assessed with CA-IX markers using the

   Composite Score (range 0-6):

   Computed by using the coded values of Percentage of Tumor Cells Staining Score (0-3) multiplied by the coded value of Staining Intensity Score (0-2).

8. Relationship of Copper Cu 64-ATSM Uptake T/M Ratio and VEGF Percentage of Tumor Cells Staining Score as a Marker of Tumor Hypoxia [ Time Frame: baseline ]

   The Ratio of Tissue to Muscle (T/M) agent uptake measured at baseline was used as a predictor of Hypoxia Tumor Hypoxia was assessed with VEGF markers using the

   Percentage of Tumor Cells Staining Score:

   0=<1% tumor cells; 1=1 33% tumor cells; 2=34 66% tumor cells; and 3=>66% tumor cells.

9. Relationship of Copper Cu 64-ATSM Uptake T/M Ratio and Vascular Endothelial Growth Factor (VEGF) Staining Intensity Score: as a Marker of Tumor Hypoxia [ Time Frame: baseline ]

   The Ratio of Tissue to Muscle (T/M) agent uptake measured at baseline was used as a predictor of Hypoxia Tumor Hypoxia was assessed with Vascular endothelial growth factor (VEGF) markers using the

   Staining Intensity Score:

   0=No staining; 1=Weak staining; and 2=Moderate to strong staining.

10. Relationship of Copper Cu 64-ATSM Uptake T/M Ratio and Vascular Endothelial Growth Factor (VEGF) Composite Score as a Marker of Tumor Hypoxia [ Time Frame: Baseline ]

    The Ratio of Tissue to Muscle (T/M) agent uptake measured at baseline was used as a predictor of Hypoxia Tumor Hypoxia was assessed with Vascular endothelial growth factor (VEGF) markers using the

    Composite Score (range 0-6):

    Computed by using the coded values of Percentage of Tumor Cells Staining Score (0-3) multiplied by the coded value of Staining Intensity Score (0-2).

11. Relationship of Copper Cu 64-ATSM Uptake T/M Ratio and Glucose Transporter 1 (GLUT1) Percentage of Tumor Cells Staining Score as a Marker of Tumor Hypoxia [ Time Frame: baseline ]

    The Ratio of Tissue to Muscle (T/M) agent uptake measured at baseline was used as a predictor of Hypoxia Tumor Hypoxia was assessed with Glucose transporter 1 (GLUT1) markers using the

    Percentage of Tumor Cells Staining Score:

    0=<1% tumor cells; 1=1 33% tumor cells; 2=34 66% tumor cells; and 3=>66% tumor cells.

12. Relationship of Copper Cu 64-ATSM Uptake T/M Ratio and Glucose Transporter 1 (GLUT1) Staining Intensity Score: as a Marker of Tumor Hypoxia [ Time Frame: baseline ]

    The Ratio of Tissue to Muscle (T/M) agent uptake measured at baseline was used as a predictor of Hypoxia Tumor Hypoxia was assessed with GLUT-1 markers using the

    Staining Intensity Score:

    0=No staining; 1=Weak staining; and 2=Moderate to strong staining.

13. Relationship of Copper Cu 64-ATSM Uptake T/M Ratio and Glucose Transporter 1 (GLUT1) Composite Score as a Marker of Tumor Hypoxia [ Time Frame: Baseline ]

    The Ratio of Tissue to Muscle (T/M) agent uptake measured at baseline was used as a predictor of Hypoxia Tumor Hypoxia was assessed with Glucose transporter 1 (GLUT1) markers using the

    Composite Score (range 0-6):

    Computed by using the coded values of Percentage of Tumor Cells Staining Score (0-3) multiplied by the coded value of Staining Intensity Score (0-2).

14. Relationship Between Copper Cu 64-ATSM Uptake and Development of Distant Metastasis [ Time Frame: every 3 months for first 2 years and every 6 months during year 3, up to 3 years ]
    Existence of distant metastasis was evaluated every 3 months for first 2 years and every 6 months during year 3 Copper Cu 64-ATSM Uptake (T/M) measured within 14 days of baseline;

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: Female
• Accepts Healthy Volunteers: No

Criteria

DISEASE CHARACTERISTICS:

• Histologically confirmed primary invasive cervical squamous cell carcinoma

  • Newly diagnosed disease
  • Stage IB2 - IVA disease based on FIGO staging system

• Plan to receive standard of care treatment with concurrent cisplatin and radiation therapy (external beam and brachytherapy) per NCCN guidelines

  • Must be scheduled to receive 6 weekly courses of cisplatin

• Meets 1 of the following criteria:

  • Pelvic nodal (or no nodal) disease only by FDG-PET/CT scan within 4 weeks of enrollment
  • Para-aortic nodal metastasis by FDG-PET/CT scan within 4 weeks of enrollment, and patient will undergo radiotherapy to para-aortic nodes
  • FDG-PET/CT scan at baseline if not meeting any of the above criteria
• No stage IVB disease (distant metastases or supraclavicular metastasis) confirmed by FDG-PET/CT scan
• No recurrent invasive carcinoma of the uterine cervix regardless of previous treatment
• No know metastases to lungs, supraclavicular lymph nodes, or other organs outside of the pelvis or abdominal lymph nodes at time of diagnosis

PATIENT CHARACTERISTICS:

• Karnofsky performance status 70-100%
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• Able to lie flat for the duration of the PET/CT scan
• No septicemia or severe infection
• No uncontrolled or poorly controlled diabetes
• No circumstances that would prevent completion of imaging studies or required clinical follow-up
• No other prior or concurrent invasive malignancies, with the exception of non-melanoma skin cancer, within the past 5 years

PRIOR CONCURRENT THERAPY:

• See Disease Characteristics
• No prior pelvic or abdominal lymphadenectomy
• No prior pelvic radiation therapy
• No previous cancer treatment contraindicates this protocol therapy

Contacts and Locations

Locations

United States, California

USC/Norris Comprehensive Cancer Center and Hospital

Los Angeles, California, United States, 90089-9181

United States, Missouri

Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis

Saint Louis, Missouri, United States, 63110

Sponsors and Collaborators

American College of Radiology Imaging Network

National Cancer Institute (NCI)

Investigators

• Principal Investigator: Farrokh Dehdashti, MD; Mallinckrodt Institute of Radiology at Washington University Medical Center
• Study Chair: David A. Mankoff, MD, PhD; University of Washington

More Information

Additional Information:

National Cancer Institute's Clinical trial database 

• Responsible Party: American College of Radiology Imaging Network
• ClinicalTrials.gov Identifier: NCT00794339
• Other Study ID Numbers: CDR0000624407; ACRIN-6682 ( Other Grant/Funding Number: ACRIN Foundation ); U01CA080098 ( U.S. NIH Grant/Contract ); U01CA079778 ( U.S. NIH Grant/Contract )
• First Posted: November 20, 2008
• Results First Posted: January 28, 2021
• Last Update Posted: February 23, 2021
• Last Verified: February 2021

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: Yes
• Plan Description: See NCI data Sharing Policy
• Supporting Materials: Study Protocol; Informed Consent Form (ICF)
• Time Frame: July 2009
• Access Criteria: Public

Keywords provided by American College of Radiology Imaging Network:

cervical squamous cell carcinoma; stage IIB cervical cancer; stage III cervical cancer; stage IV cervical cancer; stage IVA cervical cancer; stage IB cervical cancer; stage IIA cervical cancer

Additional relevant MeSH terms:

Uterine Cervical Neoplasms; Uterine Neoplasms; Genital Neoplasms, Female; Urogenital Neoplasms; Neoplasms by Site; Neoplasms; Uterine Cervical Diseases; Uterine Diseases; Fluorodeoxyglucose F18; Radiopharmaceuticals; Molecular Mechanisms of Pharmacological Action